|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date17 Nov 1995 |
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.
Start Date31 Dec 2024 |
Sponsor / Collaborator- |
100 Clinical Results associated with Reactive oxygen species x Top II x DNA
100 Translational Medicine associated with Reactive oxygen species x Top II x DNA
0 Patents (Medical) associated with Reactive oxygen species x Top II x DNA